Clinical trials: HIV1 Infection
HIV-1-infection, Mental Health Issue
SYV: A Mental Health Intervention to Improve HIV Outcomes in Tanzanian Youth
The overall objectives of this proposal are to support positive coping strategies that bolster mental health and lead to improved HIV outcomes among Young People Living with HIV (YPLWH).
- Conditions
- HIV-1-infection, Mental Health Issue, Adherence, Medication
- Trial name
- NCT05374109
- Testing
- SYV: Sauti ya Vijana (The Voice of Youth intervention)
- Where
- 6 sites in Tanzania
- Volunteers
- 690 people
- Sponsor
- Duke University
HIV Infections
Safety of and Immune Response to a DNA HIV Vaccine (VRC-HIVDNA009-00-VP) in HIV Infected Individuals With Acute HIV Infection
The purpose of this study is to evaluate whether the HIV vaccine VRC-HIVDNA009-00-VP will be safe in individuals who started antiretroviral therapy during acute HIV-1 infection.
- Trial name
- NCT00125099
- Testing
- VRC-HIVDNA009-00-VP
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, HIV-1-infection
HIV Drug Resistance Pattern Due to Migration in Poland
According to the Polish governmental statistics migration of people from Ukraine to Poland is growing and only in year 2020 have come to Poland about a quarter of a million of Ukrainian migrants.
- Conditions
- HIV Infections, HIV-1-infection, Resistant Infection
- Trial name
- NCT04636736
- Testing
- HIV drug resistance testing
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Warsaw
HIV Infections
Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients
This pilot study focuses on the persistence of central nervous system (CNS) immune activation that has been observed in the presence of 'effective' combination antiretroviral therapy (cART).
- Trial name
- NCT00672932
- Testing
- raltegravir
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of California, San Francisco
HIV Infections
Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents
Dolutegravir (DTG) is an HIV drug in the integrase inhibitor drug class. This study evaluated the pharmacokinetics (PK), safety, tolerability of and immune response to DTG when used concurrently with optimized background therapy…
- Trial name
- NCT01302847
- Testing
- DTG film-coated tablets, DTG granules for suspension, DTG dispersible tablets
- Where
- 33 sites in United States, Botswana and 6 more
- Volunteers
- 181 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption
The purpose of this study is to evaluate the safety, tolerability, and efficacy of N-803, an IL-15 superagonist, with or without combination broadly neutralizing antibodies (bNAbs), to induce HIV-1 control during analytic…
- Trial name
- NCT04340596
- Testing
- N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074
- Where
- 14 sites in United States
- Volunteers
- 118 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
Sevelamer for Reducing Endotoxemia and Immune Activation
HIV-infected people can have an increase in inflammation in their body organs, even after taking anti-HIV medicines. Sevelamer carbonate is used to bind phosphate in dialysis patients.
- Trial name
- NCT01543958
- Testing
- Sevelamer carbonate
- Where
- 15 sites in United States
- Volunteers
- 40 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infections
Tambua Mapema Plus - to Discover HIV Infection Early and Prevent Onward Transmission
This study will assess the impact of an HIV-1 RNA testing intervention targeting adult patients aged 18-39 years who seek urgent care for symptoms at primary care facilities and meet specific risk criteria for acute HIV…
- Trial name
- TMP (NCT03508908)
- Testing
- HIV-1 RNA testing
- Where
- Kenya
- Volunteers
- 2,887 people
- Sponsor
- University of Oxford
Neuropathy
Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy
The purpose of this study is to evaluate the efficacy of pregabalin compared to placebo in reducing neuropathic pain associated with HIV neuropathy.
- Trial name
- NCT01049217
- Testing
- pregabalin
- Where
- 63 sites in United States, Colombia and 7 more
- Volunteers
- 377 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
ART Adherence, HIV-1-infection
Call for Life Youth ART Adherence Study
Study purpose: To assess effect of mHealth Call for life Uganda tool (CFLU) on ART adherence among youth measured by interactive voice response to daily adherence calls mapped in the database and proportion with viral suppression…
- Conditions
- ART Adherence, HIV-1-infection, mHealth
- Trial name
- C4L-Youth (NCT04718974)
- Testing
- mHealth call for life system/ tool using IVR ( interactive voice response)
- Where
- Uganda
- Volunteers
- 206 people
- Sponsor
- Makerere University
HIV Infections
Immunomodulators on HIV-1 Reservoir
The goal of this clinical trial is to learn about the function of immunomodulators in reducing HIV reservoir. The main questions it aims to answer are: Are immunomodulators able to reduce HIV reservoirs? How do immunomodulators…
- Trial name
- NCT05598580
- Testing
- Lenalidomide, Adenosylmethionine
- Where
- China
- Volunteers
- 48 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
HIV Seropositivity
Prevalence of Cerebral Small Vessel Disease in HIV Infected Patients
Cerebral small vessel disease (CSVD) is a major cause of cognitive impairment and disability in the general population, secondary to the accumulation of asymptomatic elementary lesions.
- Trial name
- MICROBREAK1 (NCT02082574)
- Where
- France
- Volunteers
- 655 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Hepatic Steatosis, HIV-1-infection
Adding MAraViroc &/or METformin for Hepatic Steatosis in People Living With HIV
This is a multicentre, phase IV, randomised, open-label, trial exploring adjunctive maraviroc and/or metformin for liver steatosis over 48 weeks.
- Trial name
- MAVMET (NCT03129113)
- Testing
- Maraviroc, Metformin
- Where
- 6 sites in United Kingdom
- Volunteers
- 90 people
- Sponsor
- University College, London
HIV-1-infection
Implication for Strategies of Long Term Control of Viral Replication in Patient With Primary HIV Infection (PHI).
Multicenter, parallel group, randomised, open label, study. Twenty-five clinical centers constituting the InAction network will participate the study.
- Trial name
- P25-INACTION (NCT04225325)
- Testing
- SYMTUZA, DESCOVY+DOLUTEGRAVIR, SYMTUZA+DOLUTEGRAVIR
- Where
- Italy
- Volunteers
- 112 people
- Sponsor
- ADRIANO LAZZARIN, MD
HIV-1-infection, Hypertension
Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV
Social distancing measures put in place to combat the COVID-19 disease pandemic may increase social isolation and impact cardiovascular disease prevention behaviors among people living with HIV (PLWH).
- Trial name
- AAIM-High (NCT04661813)
- Testing
- EXTRA-CVD Virtual Care
- Where
- 3 sites in United States
- Volunteers
- 81 people
- Sponsor
- Case Western Reserve University
HIV Infections
A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART)
The use of a Bioject 2000 needle free injection device (NFID) and a compressed immunization schedule will be safely tolerated and will augment the immunogenicity of the HIV-1 CTL epitope DNA vaccine (EP1090) in HIV-1 infected…
- Trial name
- EP1090 (NCT00532974)
- Testing
- EP1090
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Epimmune
HIV Infections
Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults
The purpose of this study is to test the safety of an HIV DNA vaccine (EP HIV-1090) and to test whether or not the vaccine can stimulate immune system responses in HIV uninfected people.
- Trial name
- NCT00054860
- Testing
- EP HIV-1090
- Where
- 5 sites in United States, Botswana
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS
Efficacy and Safety of Ainuovirine Treating With AIDS Patients
Ainuovirine is the third generation of non nucleoside reverse transcriptase inhibitors(NNRTIs), for the treatment of HIV-1 infected adults.
- Trial name
- ESATA (NCT05420246)
- Testing
- Ainuovirine
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Guangzhou 8th People's Hospital
HIV Infections
HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study
This study evaluated the safety, immunogenicity, and preliminary assessment of efficacy of a novel vaccine encoding conserved elements (CE) of the HIV-1 Gag core protein, p24Gag, as a therapeutic vaccine in HIV-1 infected persons…
- Trial name
- NCT03560258
- Testing
- p24CE1/2 pDNA vaccine, p24CE1/2 pDNA vaccine admixed with full-length p55^gag pDNA vaccine, Full-length p55^gag pDNA vaccine
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 45 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Hepatitis C
The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin
This study will evaluate how controlling HIV infection with HAART (highly active antiretroviral therapy) affects the response to hepatitis C treatment with peginterferon alpha-2b and ribavirin in HIV-infected patients with…
- Trial name
- NCT00031343
- Testing
- highly active antiretroviral therapy (HAART)
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)